Thank You
References
1. Burstein HJ, Gelber S, Guadagnoli E, Weeks JC (1999) Use of alternative
medicine by women with early-stage breast cancer. N Engl J Med 340:
1733–1739.
2. Broxterman HJ, Georgopapadakou NH (2007) Anticancer therapeutics: a surge
of new developments increasingly target tumor and stroma. Drug Resist Updat
10: 182–193.
3. Liu JR, Opipari AW, Tan L, Jiang Y, Zhang Y, et al. (2002) Dysfunctional
apoptosome activation in ovarian cancer: implications for chemoresistance.
Cancer Res 62: 924–931.
4. Nishio M, Koshikawa T, Kuroishi T, Suyama M, Uchida K, et al. (1996)
Prognostic significance of abnormal p53 accumulation in primary, resected nonsmall-
cell lung cancers. J Clin Oncol 14: 497–502.
5. Nishio M, Koshikawa T, Yatabe Y, Kuroishi T, Suyama M, et al. (1997)
Prognostic significance of cyclin D1 and retinoblastoma expression in
combination with p53 abnormalities in primary, resected non-small cell lung
cancers. Clin Cancer Res 3: 1051–1058.
6. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, et al. (2005) Mutations of
the epidermal growth factor receptor gene predict prolonged survival after
gefitinib treatment in patients with non-small-cell lung cancer with postoperative
recurrence. J Clin Oncol 23: 2513–2520.
7. Nusse R, Theunissen H, Wagenaar E, Rijsewijk F, Gennissen A, et al. (1990)
The Wnt-1 (int-1) oncogene promoter and its mechanism of activation by
insertion of proviral DNA of the mouse mammary tumor virus. Mol Cell Biol
10: 4170–4179.
8. Beachy PA, Karhadkar SS, Berman DM (2004) Tissue repair and stem cell
renewal in carcinogenesis. Nature 432: 324–331.
9. Holcombe RF, Marsh JL, Waterman ML, Lin F, Milovanovic T, et al. (2002)